Wells Fargo
PRME icon

Wells Fargo’s Prime Medicine PRME Stock Holding History

Wells Fargo’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$929K Sell
251,747
-67,803
-21% -$225K ﹤0.01% 4162
2026
Q1 		$1.11M Buy
319,550
+25,054
+9% +$95.4K ﹤0.01% 3682
2025
Q4 		$1.02M Buy
294,496
+97,482
+49% +$434K ﹤0.01% 3953
2025
Q3 		$1.09M Buy
197,014
+95,863
+95% +$389K ﹤0.01% 3752
2025
Q2 		$250K Buy
101,151
+10,332
+11% +$15.9K ﹤0.01% 4638
2025
Q1 		$181K Sell
90,819
-5,362
-6% -$13.7K ﹤0.01% 4780
2024
Q4 		$281K Sell
96,181
-75,287
-44% -$264K ﹤0.01% 4578
2024
Q3 		$664K Buy
171,468
+151,110
+742% +$700K ﹤0.01% 3815
2024
Q2 		$105K Buy
20,358
+8,548
+72% +$51.8K ﹤0.01% 4914
2024
Q1 		$82.7K Buy
11,810
+1,581
+15% +$12K ﹤0.01% 5002
2023
Q4 		$90.6K Sell
10,229
-21,088
-67% -$162K ﹤0.01% 4968
2023
Q3 		$299K Buy
31,317
+15,020
+92% +$195K ﹤0.01% 4103
2023
Q2 		$239K Buy
16,297
+14,361
+742% +$200K ﹤0.01% 4476
2023
Q1 		$23.8K Buy
+1,936
New +$31.5K ﹤0.01% 5567

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Wells Fargo's PRME Position: Q2 2026 in Review

Wells Fargo reduced its Prime Medicine (PRME) stake by 21% in Q2 2026, selling an estimated $225K and leaving 251,747 shares worth $929K. The position accounts for ﹤0.01% of the portfolio, ranked #4162.

Wells Fargo first reported a position in PRME in Q1 2023 and has held it in 14 quarters since. The position peaked at $1.11M in Q1 2026. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Wells Fargo held 251,747 shares of Prime Medicine worth $929K as of Q2 2026.
  • Wells Fargo sold 67,803 Prime Medicine shares in Q2 2026, an estimated $225K.
  • Prime Medicine made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4162 holding.
  • Wells Fargo first reported a position in Prime Medicine in Q1 2023 and has held it in 14 quarters since.
  • Wells Fargo's Prime Medicine position peaked at $1.11M in Q1 2026.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.